- The new cGMP line in Visp is fully operational with first customer batches in April 2023.
- The facility spans 1,200 sqm and includes a state-of-the-art vial filling isolator line.
- The expansion follows a CHF 500 million investment in a new facility in Stein.
- The Visp line complements bioconjugation, mammalian manufacturing, and microbial development expansions.
New cGMP Line in Visp
Lonza has completed a new cGMP clinical and commercial drug product manufacturing line in Visp, Switzerland. The 1,200 sqm facility includes a state-of-the-art liquid and lyophilized vial filling isolator line, meeting GMP Annex 1 requirements for sterile products. The line is fully operational, with the first customer batches scheduled for April 2023.
Expansion and Investment
This development is part of Lonza’s Ibex® Biopark and complements recent expansions at the Visp site, including bioconjugation, mammalian manufacturing, and microbial development. These expansions align with Lonza’s strategy to build capacity in high-demand areas and provide end-to-end solutions from drug substance to drug product at a single location.
Milestone in Drug Product Services
The completion of the Visp line marks a significant milestone for Lonza’s Drug Product Services (DPS). It follows the groundbreaking of a new large-scale commercial drug product facility in Stein, Switzerland, which involves an investment of approximately CHF 500 million. This ongoing investment aims to expand the DPS network, offering comprehensive solutions across the product lifecycle, including clinical and commercial supply.
Support from Basel Facility
The new manufacturing line in Visp will be supported by Lonza’s Drug Product Center of Excellence in Stücki Technology Park, Basel. The Stücki facility provides a range of drug product development services, including formulation and process development, analytical development, and quality control.
